Novo Nordisk Enhances Patient Accessibility to Wegovy® with WeightWatchers Collaboration

Novo Nordisk Partners with WeightWatchers to Improve Accessibility to Wegovy®

In a significant move to enhance patient access to effective obesity treatments, Novo Nordisk has announced a collaboration with WeightWatchers, a leader in science-backed weight management. This partnership aims to streamline access to the FDA-approved medication, Wegovy® (semaglutide injection 2.4 mg), through the NovoCare® Pharmacy network, starting July 1, 2025. This initiative is designed to support individuals living with obesity by providing a comprehensive, integrated experience that includes lifestyle support to improve health outcomes.

A Focus on Patient Safety and Convenience

Novo Nordisk's commitment to patient safety is a cornerstone of this new collaboration. Novo Nordisk's Executive Vice President of U.S. Operations, Dave Moore, emphasized that as the landscape of healthcare evolves, the company is focused on ensuring accessible care for those living with chronic obesity. WeightWatchers, with over six decades of expertise in healthy weight management, brings a proven approach that aligns with Novo Nordisk's mission to improve long-term health outcomes for patients.

This partnership follows positive results from other collaborations with telehealth providers like Ro and LifeMD, reinforcing Novo Nordisk's strategy to work with companies that share their vision for patient-centered care. As part of this initiative, a new cash savings offer priced at $299 will be available for new self-paying patients starting July 1, 2025. This introductory rate is aimed at individuals who have previously been prescribed unapproved semaglutide and are seeking the safe, FDA-approved version. The previous offer of $199 for this medication will expire on June 30, 2025, further encouraging patients to transition to Wegovy®.

Simplified Access and Savings for Patients

Patients can easily utilize this offer by activating it at Wegovy.com, having a coupon sent directly to their mobile devices, or accessing it through partnered pharmacies and healthcare providers, including WeightWatchers, Ro, and LifeMD. The collaborative nature of this initiative allows for seamless integration of services, ensuring patients can access their medication conveniently alongside necessary lifestyle support.

Wegovy® has been shown to aid individuals aged 12 and older in their weight loss journey, particularly for those with obesity or weight-related medical conditions. This collaboration highlights Novo Nordisk's commitment to ensuring that patients receive authentic medications in compliance with FDA regulations, especially given the risks associated with unregulated